Clinical trials: Transthyretin Cardiac Amyloidosis
Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Global Prevalence of ATTR-CM in Participants With HFpEF
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved…
- Trial name
- NCT04424914
- Testing
- Scintigraphy
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Amyloid Transthyretin Cardiomyopathy
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an open-label extension phase in subjects with…
- Trial name
- NCT04360434
- Testing
- NI006
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 46 people
- Sponsor
- Neurimmune AG
Transthyretin Amyloid Cardiomyopathy
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
This is a national, multi-center, single-arm study, open-label to patients with symptomatic Transthyretin amyloid cardiomyopathy (ATTR-CM) who are tafamidis naïve.
- Trial name
- NCT04814186
- Testing
- Tafamidis
- Where
- 9 sites in China
- Volunteers
- 53 people
- Sponsor
- Pfizer
Transthyretin-type Cardiac Amyloidosis
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
- Trial name
- ATTR-CM (NCT07306949)
- Testing
- Acoramidis
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Polyneuropathy, Amyloid, Neuropathic Pain
Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)
An International, multicenter, epidemiological observational study investigating the prevalence of Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR-FAP) in participants with small fiber polyneuropathy of no obvious…
- Conditions
- Polyneuropathy, Amyloid, Neuropathic Pain, Cardiac Failure, Orthostatic Hypotension
- Trial name
- TRAP2-1 (NCT01705626)
- Where
- 11 sites in Austria, Hungary and 4 more
- Volunteers
- 500 people
- Sponsor
- CENTOGENE GmbH Rostock
Amyloid Cardiomyopathy, Wild Type ATTR Amyloidosis
Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy
The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.
- Trial name
- NCT06261216
- Testing
- Interview
- Where
- Austria
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Aortic Stenosis, Transthyretin Amyloidosis
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission…
- Conditions
- Aortic Stenosis, Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
- Trial name
- NCT04899180
- Testing
- 99mTc-PYP
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
- Trial name
- NCT06128629
- Testing
- NTLA-2001
- Where
- 138 sites in United States, Argentina and 24 more
- Volunteers
- 1,200 people
- Sponsor
- Intellia Therapeutics
Transthyretin Amyloid Cardiopathy
ION-682884 in Patients With TTR Amyloid Cardiomyopathy
Transthyretin is a protein produced in the liver that transports thyroid hormone and vitamin A. A single substitution of an amino acid in the structure of TTR can result in a relatively unstable protein, the breakdown products of…
- Trial name
- NCT04843020
- Testing
- ION 682884
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Hereditary Transthyretin Amyloidosis, Carpal Tunnel Syndrome
Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
This is a multicenter observational study consisting of retrospective and prospective phases. The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who underwent…
- Conditions
- Hereditary Transthyretin Amyloidosis, Carpal Tunnel Syndrome, Polyneuropathy, Amyloidosis
- Trial name
- LOCUS (NCT06414746)
- Where
- 13 sites in Russia
- Volunteers
- 721 people
- Sponsor
- AstraZeneca
Wild-type ATTR Amyloidosis, Amyloidosis Cardiac
ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers
This study explores whether extracellular vesicles (EVs) tiny particles released into the bloodstream by cells can serve as early and minimally invasive biomarkers for transthyretin amyloid cardiomyopathy (ATTR-CM).
- Conditions
- Wild-type ATTR Amyloidosis, Amyloidosis Cardiac, Amyloidosis, Hereditary, Amyloidosis Transthyretin
- Trial name
- EV-ATTR (NCT07314268)
- Where
- Brazil
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Transthyretin Cardiac Amyloidosis, Light Chain Cardiac Amyloidosis
[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis
This is a first in human study that will assess the safety, pharmacokinetics, biodistribution and diagnostic performance of [18F]FIDT-10b (fluorine-18 labeled FIDT-10b), a positron emission tomography (PET) agent.
- Trial name
- FIDTCA (NCT07835880)
- Testing
- [18F]FIDT-10b, 99mTc-PYP
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
ATTR-PN
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
This is a Phase 3, open-label study designed to obtain additional long-term safety and efficacy data for oral tafamidis (20 mg soft gelatin capsule) administered once daily (QD).
- Trial name
- NCT00925002
- Testing
- Tafamidis
- Where
- 9 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- Pfizer
Transthyretin Amyloidosis, Cardiomyopathy
Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
The primary objective for this study is to evaluate the efficacy of doxycycline + ursodeoxycholic acid (UDCA) on disease progression in Transthyretin Amyloidosis (ATTR) subjects with cardiomyopathy with or without neuropathy.
- Trial name
- Dox/Urso (NCT02016365)
- Testing
- Doxycycline, Ursodeoxycholic acid
- Where
- 3 sites in Sweden
- Volunteers
- 55 people
- Sponsor
- Umeå University
Amyloidosis, Amyloidosis Cardiac
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines…
- Conditions
- Amyloidosis, Amyloidosis Cardiac, ATTR Amyloidosis Wild Type
- Trial name
- NOTE-ATTR (NCT06251778)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Paolo Milani
Amyloidosis, Trigger Finger
Cardiac Amyloidosis Screening at Trigger Finger Release
The investigators will prospectively evaluate for the presence of amyloid deposits in soft tissue samples obtained from patients undergoing trigger finger release surgery.
- Conditions
- Amyloidosis, Trigger Finger, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
- Trial name
- CAST (NCT03886155)
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- The Cleveland Clinic
Amyloidosis
The Effect of Diflunisal on Familial Transthyretin Amyloidosis
An ongoing trial of diflunisal has been closed for enrollment, thus, patients suitable for the study can no longer participate or receive treatment by diflunisal; and patients, who have participated in the trial can not continue…
- Trial name
- DFNS01 (NCT01432587)
- Testing
- Diflunisal
- Where
- 3 sites in Sweden
- Volunteers
- 55 people
- Sponsor
- Umeå University
Amyloidosis, Transthyretin Amyloid Cardiomyopathy
carDIo-ttranSSfOrm nucLEar Imaging Study
The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
- Trial name
- DISSOLvE (NCT05259072)
- Testing
- 99m-technetium pyrophosphate scintigraphy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Oregon Health and Science University
Wild-type Transthyretin Amyloidosis
Prevalence of Wild Type ATTR
Prospective, observational, single-centre, non-interventional study aiming at reporting the prevalence of ATTRwt in patients with lumbar spinal stenosis (LSS).
- Trial name
- NCT03966105
- Testing
- HE and Congo red staining
- Where
- Switzerland
- Volunteers
- 94 people
- Sponsor
- Oncology Institute of Southern Switzerland
Transthyretin Cardiac Amyloidosis
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis
The goal of this clinical trial is to learn if trimetazidine can improve blood flow in the heart in adults with transthyretin cardiac amyloidosis (ATTR-CM).
- Trial name
- TACT-TTR (NCT07836699)
- Testing
- Trimetazidine
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Fábio Fernandes